Inactive Instrument

Genentech, Inc. Stock

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

2015	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
2009	GENENTECH : Roche buys Genentech for $46.8 billion	RE

Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	15-02-16	CI
GENENTECH : Roche buys Genentech for $46.8 billion	09-03-12	RE
GENENTECH : Roche increases Genentech offer to $45.7 billion	09-03-06	RE
GENENTECH : gives long-term forecast to fend off Roche	09-03-02	RE
GENENTECH : to make case for higher purchase price	09-02-27	RE
GENENTECH : asks shareholders to hold off on Roche bid	09-02-09	RE
GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion	09-01-30	RE
GENENTECH : forecast disappoints	09-01-15	RE
GENENTECH : profit up, forecast light	09-01-15	RE
GENENTECH : profit rises, sales top estimates	08-10-14	RE
GENENTECH : 3rd-quarter profit rises	08-10-14	RE
GENENTECH : rejects Roche bid but willing to talk	08-08-13	RE
GENENTECH : rejects Roche bid	08-08-13	RE

Genentech, Inc. : Dalradian Appoints Chief Operating Officer	11-04-20	PU
Genentech, Inc. : Dalradian Appoints Chief Operating Officer	11-04-20	PU
GENENTECH : Roche Completes Acquisition of Genentech	09-03-26	PR
GENENTECH : Roche Completes Tender Offer for Genentech	09-03-26	PR
GENENTECH : Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation	09-03-12	PR

Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie	16-04-12
Roche erhält von FDA Zulassung für Venetoclax zur Behandlung von Leukämie-Art	16-04-11
Genentech : Roche détient 93,2% du capital.	09-03-26
GENENTECH : Roche détient 93,2% de Genentech à l'issue de son offre	09-03-26
GENENTECH : Roche parvient à ses fins avec Genentech	09-03-12

Sector